What is the address of VERHELST-KUPPER, MEDICAL?

The registered office of VERHELST-KUPPER, MEDICAL is located at Rue Falise 39, 1470 Genappe.

Is VERHELST-KUPPER, MEDICAL still active?

Yes. According to the CBE (28 September 2026) VERHELST-KUPPER, MEDICAL is active, legal situation “Normale toestand”, started on 4 February 2016.

Is VERHELST-KUPPER, MEDICAL registered on Peppol?

No, VERHELST-KUPPER, MEDICAL is currently not registered on the Peppol network.

What is the enterprise number of VERHELST-KUPPER, MEDICAL?

The enterprise number of VERHELST-KUPPER, MEDICAL is BE0647798662.

When was VERHELST-KUPPER, MEDICAL founded?

VERHELST-KUPPER, MEDICAL was founded on 4 February 2016.

Who are the directors of VERHELST-KUPPER, MEDICAL?

According to the 2025 annual accounts, the directors of VERHELST-KUPPER, MEDICAL are: Marie-Sophie Kupper, Farnçois Verhelst.

Is VERHELST-KUPPER, MEDICAL a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 4 February 2016; 5 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did VERHELST-KUPPER, MEDICAL make in 2025?

VERHELST-KUPPER, MEDICAL posted a profit after taxes of € 197,081 in financial year 2025.

What is the revenue of VERHELST-KUPPER, MEDICAL?

As a small company, VERHELST-KUPPER, MEDICAL is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 334,203.

VERHELST-KUPPER, MEDICAL (Private Limited) - Genappe

Dossier VERHELST-KUPPER, MEDICAL, printed on 28 September 2026 from databakkes.be/en/0647798662/verhelst-kupper-medical. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Not on Peppol Peppol

Not registered in the Peppol network, mandatory for VAT-liable companies since 1 January 2026.

Financials

Financial year 2025

VERHELST-KUPPER, MEDICAL from Genappe, company number BE0647798662, closed financial year 2025 with a result of € 197,081 after tax. For that financial year VERHELST-KUPPER, MEDICAL recorded a gross margin of € 334,203 and equity of € 267,069. Compared with financial year 2024, the result moved from € 170,352 to € 197,081. Profitable, and profit is growing. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 13, 2026.

What it is worth Healthy

€ 267,069

▼ 5% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 197,081

▲ 16% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 188,963

▲ 7% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 210,000 paid out

More than the year’s profit went to the shareholders; reserves fell.

People and assets in 2025

Vehicles and equipment

€ 76,100

▲ 1% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

€ 16,690

▼ 63% vs 2024

Loans from banks and other lenders, long and short.

Owed to suppliers

€ 1,787

▼ 80% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 8,167

▼ 73% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 336,948 Gross margin 2022: € 336,948 First fiscal year in the series	€ 311,734 Gross margin 2023: € 311,734 ▼ 7% vs 2022 (€ 336,948) Unfavourable step	€ 296,218 Gross margin 2024: € 296,218 ▼ 5% vs 2023 (€ 311,734) Unfavourable step	€ 334,203 Gross margin 2025: € 334,203 ▲ 13% vs 2024 (€ 296,218) Favourable step	▲ 13%
Profit after taxes	€ 212,839 Profit after taxes 2022: € 212,839 First fiscal year in the series	€ 189,698 Profit after taxes 2023: € 189,698 ▼ 11% vs 2022 (€ 212,839) Unfavourable step	€ 170,352 Profit after taxes 2024: € 170,352 ▼ 10% vs 2023 (€ 189,698) Unfavourable step	€ 197,081 Profit after taxes 2025: € 197,081 ▲ 16% vs 2024 (€ 170,352) Favourable step	▲ 16%
Equity	€ 189,938 Equity 2022: € 189,938 First fiscal year in the series	€ 309,637 Equity 2023: € 309,637 ▲ 63% vs 2022 (€ 189,938) Favourable step	€ 279,988 Equity 2024: € 279,988 ▼ 10% vs 2023 (€ 309,637) Unfavourable step	€ 267,069 Equity 2025: € 267,069 ▼ 5% vs 2024 (€ 279,988) Unfavourable step	▼ 5%
Total debts	€ 329,298 Total debts 2022: € 329,298 First fiscal year in the series	€ 151,694 Total debts 2023: € 151,694 ▼ 54% vs 2022 (€ 329,298) Favourable step	€ 254,056 Total debts 2024: € 254,056 ▲ 67% vs 2023 (€ 151,694) Unfavourable step	€ 213,006 Total debts 2025: € 213,006 ▼ 16% vs 2024 (€ 254,056) Favourable step	▼ 16%
Cash	€ 210,607 Cash 2022: € 210,607 First fiscal year in the series	€ 109,317 Cash 2023: € 109,317 ▼ 48% vs 2022 (€ 210,607) Unfavourable step	€ 176,329 Cash 2024: € 176,329 ▲ 61% vs 2023 (€ 109,317) Favourable step	€ 188,963 Cash 2025: € 188,963 ▲ 7% vs 2024 (€ 176,329) Favourable step	▲ 7%
Land & buildings	€ 156,033 Land & buildings 2022: € 156,033 First fiscal year in the series	€ 177,812 Land & buildings 2023: € 177,812 ▲ 14% vs 2022 (€ 156,033) Unchanged	€ 204,157 Land & buildings 2024: € 204,157 ▲ 15% vs 2023 (€ 177,812) Unchanged	€ 189,856 Land & buildings 2025: € 189,856 ▼ 7% vs 2024 (€ 204,157) Unchanged	▼ 7%
Retained profit	€ 171,338 Retained profit 2022: € 171,338 First fiscal year in the series	€ 291,037 Retained profit 2023: € 291,037 ▲ 70% vs 2022 (€ 171,338) Favourable step	€ 261,388 Retained profit 2024: € 261,388 ▼ 10% vs 2023 (€ 291,037) Unfavourable step	€ 248,469 Retained profit 2025: € 248,469 ▼ 5% vs 2024 (€ 261,388) Unfavourable step	▼ 5%
Dividend	€ 190,000 Dividend 2022: € 190,000 First fiscal year in the series	€ 70,000 Dividend 2023: € 70,000 ▼ 63% vs 2022 (€ 190,000) Unchanged	€ 200,000 Dividend 2024: € 200,000 ▲ 186% vs 2023 (€ 70,000) Unchanged	€ 210,000 Dividend 2025: € 210,000 ▲ 5% vs 2024 (€ 200,000) Unchanged	▲ 5%
Bank debt	€ 118,043 Bank debt 2022: € 118,043 First fiscal year in the series	€ 79,998 Bank debt 2023: € 79,998 ▼ 32% vs 2022 (€ 118,043) Favourable step	€ 44,999 Bank debt 2024: € 44,999 ▼ 44% vs 2023 (€ 79,998) Favourable step	€ 16,690 Bank debt 2025: € 16,690 ▼ 63% vs 2024 (€ 44,999) Favourable step	▼ 63%
Balance sheet total	€ 519,237 Balance sheet total 2022: € 519,237 First fiscal year in the series	€ 461,331 Balance sheet total 2023: € 461,331 ▼ 11% vs 2022 (€ 519,237) Unchanged	€ 534,045 Balance sheet total 2024: € 534,045 ▲ 16% vs 2023 (€ 461,331) Unchanged	€ 480,076 Balance sheet total 2025: € 480,076 ▼ 10% vs 2024 (€ 534,045) Unchanged	▼ 10%

Key figures of VERHELST-KUPPER, MEDICAL, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to VERHELST-KUPPER, MEDICAL?

What happened at VERHELST-KUPPER, MEDICAL in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 13, 2026 New annual accounts for financial year 2025: profit of € 197,081 (▲ 16% vs 2024). Source: NBB ↗
Feb 4, 2016 New establishment in Genappe. KBO
Feb 4, 2016 Start of the company according to the CBE. KBO

In short

From € 212,839 profit in 2022 to € 197,081 profit in 2025.

Paid € 252,669 in corporate taxes since 2022.

Best year ever: 2022, with € 212,839 profit.

Paid out € 670,000 in dividends to the owners in total.

Original PDFs at the National Bank ↗

A new publication or filing at VERHELST-KUPPER, MEDICAL? We notify you, reason included.

Follow VERHELST-KUPPER, MEDICAL

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

Marie-Sophie Kupper Farnçois Verhelst

VERHELST-KUPPER, MEDICAL

Behind VERHELST-KUPPER, MEDICAL are Marie-Sophie Kupper and Farnçois Verhelst.

See the full network in the app

Directors

According to the 2025 annual accounts

Marie-Sophie Kupper

Director

Farnçois Verhelst

Director

Establishments

Establishment units

Physical locations of this company

Registered office

Rue Falise 39

1470 Genappe

2.250.384.558

Rue Bon Air 37

1470 Genappe

Active since 4 February 2016

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0647.798.662
VAT number: BE 0647.798.662
Registered office: Rue Falise 39, 1470 Genappe
Names & denominations: VERHELST-KUPPER, MEDICAL
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 4 February 2016
Peppol: Not registered

View on CBE Public ↗ Annual accounts (NBB) ↗